Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue

New England Journal of Medicine

Volumn 342, Issue 25, 2000, Pages 1866-1870

  Hoeper, Marius M ^a   Schwarze, Michael ^a   Ehlerding, Stefan ^a   Adler Schuermeyer, Angelika ^a   Spiekerkoetter, Edda ^a   Niedermeyer, Jost ^a   Hamm, Michael ^a   Fabel, Helmut ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ILOPROST; PROSTACYCLIN DERIVATIVE;

ADULT; AEROSOL; AGED; ARTICLE; CLINICAL ARTICLE; COUGHING; DRUG TOLERABILITY; EXERCISE; FEMALE; HEADACHE; HEMODYNAMICS; HUMAN; LONG TERM CARE; MALE; NEBULIZATION; PAIN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; AGED; EXERCISE TOLERANCE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; MIDDLE AGED; VASODILATOR AGENTS;

EID: 0034702248     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200006223422503     Document Type: Article

References (21)

1. Higenbottam TW, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984;1:1046-7.
2. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 1990;112:485-91.
3. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409-15.
4. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
5. Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997;30:343-9.
6. Hinderliter AL, Willis PW IV, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation 1997;95:1479-86.
7. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338: 273-7.
8. Grant SM, Goa KL. Iloprost: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 1992;43:889-924.
9. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996;124:820-4.
10. Olschewski H, Ghofrani HA, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension: an uncontrolled trial. Ann Intern Med 2000;132:435-43.
11. Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol 2000;35: 176-82.
12. Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999;160:600-7.
13. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216-23.
14. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. CMAJ 1985;132:919-23.
15. Hoeper MM, Maier R, Tongers J, et al. Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med 1999;160:535-41.
16. Rosner B. Fundamentals of biostatistics. 4th ed. Belmont, Calif.: Duxbury Press, 1995.
17. Hoeper MM, Voelkel NF, Bates TO, et al. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. Am J Respir Cell Mol Biol 1997;17:748-56.
18. Fishman AP. Pulmonary hypertension - beyond vasodilator therapy. N Engl J Med 1998;338:321-2.
19. Idem. Epoprostenol (prostacyclin) and pulmonary hypertension. Ann Intern Med 2000;132:500-2.
20. Gessler T, Schmehl T, Seeger W. Comparison of two inhalation systems for Ilomedin-aerosol therapy in pulmonary hypertension. Am J Respir Crit Care Med 1999;159:Suppl:A159. abstract.
21. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336: 111-7.